Forbes: Injectable glucagon-like peptide-1 agonists, or GLP-1s, were first approved as diabetes medications 20 years ago

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

BioSpace: While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Real-world, integrated data follows-up on previous insights, analytics.

Develop a holistic GLP-1 strategy An evidence-based approach to GLP-1 drugs helps you implement custom strategies that promote clinically appropriate use and consider affordability, long-term value...

Cover image for Quarterly Drug Pipeline: January 2025 Updates on promising therapies in development, focusing on drugs nearing FDA approval Prime Therapeutics /quarterly-drug-pipeline-january-2025...

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

cover image for Quarterly Drug Pipeline: October 2024 Quarterly Drug Pipeline: October 2024 Prime Therapeutics /quarterly-drug-pipeline-october-2024 Prime Therapeutics’ Quarterly Drug Pipeline...

Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

Cover image for Quarterly Drug Pipeline: October 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-october-2025...